Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Press Release: INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
新聞稿：Inovio宣佈任命Michael Cordera為執行副總裁兼總法律顧問
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
Inovio公司宣佈任命邁克爾·科德拉為執行副總裁兼總法律顧問
PR Newswire
美通社
PLYMOUTH MEETING, Pa., March 15, 2021
賓夕法尼亞州普利茅斯會議，2021年3月15日
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Officer, Dr. J. Joseph Kim. In this role, he will be responsible for the company's legal team and strategy.
亞洲網賓夕法尼亞州普利茅斯會議2021年3月15日電專注於將精確設計的DNA藥物推向市場的生物技術公司Inovio(納斯達克市場代碼：INO)今天宣佈任命邁克爾·科德拉(Michael Cordera)為執行副總裁兼總法律顧問。科德拉先生將在公司的執行領導團隊任職，並向Inovio公司總裁兼首席執行官J·約瑟夫·金博士彙報工作。在這個職位上，他將負責公司的法律團隊和戰略。
Dr. J. Joseph Kim, INOVIO's President and CEO, said, "Michael is a seasoned legal executive with deep life sciences experience both in the US and abroad. His expertise surrounding commercial operations and global business development come at a key time for our organization. He will be a valuable leader as INOVIO executes on its plans to develop and commercialize DNA medicines to treat infectious diseases, cancer, and HPV-associated diseases."
Inovio總裁兼首席執行官J.Joseph Kim博士説：“Michael是一位經驗豐富的法律高管，在美國和國外都有豐富的生命科學經驗。他在商業運營和全球業務發展方面的專業知識正值我們組織的關鍵時刻。隨着Inovio執行其開發和商業化治療傳染病、癌症和HPV相關疾病的DNA藥物的計劃，他將成為一個有價值的領導者。”
Mr. Cordera joins INOVIO from Eagle Pharmaceuticals, where he served as General Counsel and Chief Compliance Officer. Before Eagle, Michael held various legal positions of increasing responsibility at Warner Chilcot and inVentiv (now Syneos) Health where he was responsible for legal affairs in North America, Europe, and Asia. Mr. Cordera began his legal career as an Associate at Sherman & Sterling, LLP. He holds a J.D. from the Rutgers School of Law and an undergraduate degree from the American University of Paris.
科德拉先生從Eagle製藥公司加盟Inovio公司，在那裏他擔任總法律顧問和首席合規官。在Eagle之前，Michael在Warner Chilcot和InVentiv(現在的Syneos)Health擔任各種責任日益增加的法律職位，負責北美、歐洲和亞洲的法律事務。科德拉先生作為Sherman&Sterling，LLP的一名律師開始了他的法律職業生涯。他擁有羅格斯法學院(Rutgers School Of Law)的法學博士學位和巴黎美國大學(American University Of Paris)的本科學位。
About INOVIO's DNA Medicines Platform
關於Inovio的DNA藥物平臺
INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with COVID-19 and MERS, for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
英諾威公司目前有15個脱氧核糖核酸藥物臨牀項目正在開發中，重點研究人乳頭瘤病毒相關疾病、癌症和傳染病，包括與新冠肺炎和中東呼吸綜合徵相關的冠狀病毒，這些項目正在美國國防部和防疫創新聯盟的資金支持下開發。DNA藥物是由優化的DNA質粒組成的，這些質粒是由雙鏈DNA組成的小圈，通過計算機測序技術合成或重組，旨在在體內產生特定的免疫反應。
INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA(R) . The CELLECTRA(R) device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA(R) device is designed to ensure that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.
Inovio公司的DNA藥物使用Inovio公司專有的名為CELLECTRA(R)的手持智能設備，通過肌肉內或皮內直接將優化後的質粒輸送到細胞內。CELLECTRA(R)設備使用短暫的電脈衝可逆地打開細胞中的小孔，使質粒得以進入，從而克服了其他DNA和其他核酸方法(如mRNA)的一個關鍵限制。一旦進入細胞，DNA質粒就能使細胞產生目標抗原。抗原在細胞中自然處理，並觸發所需的T細胞和抗體介導的免疫反應。使用CELLECTRA(註冊商標)設備進行管理的目的是確保DNA藥物有效地直接輸送到人體細胞，在那裏它可以工作以驅動免疫反應。Inovio的DNA藥物不會以任何方式幹擾或改變個人自身的DNA。Inovio的DNA藥物平臺的優勢是設計和製造DNA藥物的速度很快；產品的穩定性，不需要在儲存和運輸過程中冷凍；以及在臨牀試驗中觀察到的強大的免疫反應、安全性和耐受性。
With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.
在一系列臨牀試驗的7000多種應用中，有3000多名患者接受了Inovio的研究DNA藥物治療，Inovio在快速產生有潛力滿足全球緊迫健康需求的DNA藥物候選藥物方面有着良好的記錄。
About INOVIO
關於Inovio
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.
Inovio是一家生物技術公司，專注於將精確設計的DNA藥物迅速推向市場，以治療和保護人們免受傳染病、癌症和與HPV相關的疾病的侵襲。Inovio是第一家也是唯一一家在臨牀上證明DNA藥物可以通過專有智能設備直接進入人體細胞，以產生強大和可耐受的免疫反應的公司。Inovio公司的主要免疫治療候選藥物VGX-3100目前正處於癌前宮頸發育不良的3期試驗，在2b期臨牀試驗中清除了高危HPV-16和/或HPV-18。高危HPV導致70%的宮頸癌、91%的肛門癌和69%的外陰癌。同時還在開發針對人乳頭瘤病毒相關癌症和一種罕見的人乳頭瘤病毒相關疾病(複發性呼吸道乳頭狀瘤病)、非人乳頭瘤病毒相關癌症、多形性膠質母細胞瘤和前列腺癌的項目，以及針對與新冠肺炎疾病和中東呼吸綜合徵、拉沙熱、埃博拉病毒和艾滋病相關的冠狀病毒的傳染病DNA疫苗開發項目。合作伙伴和合作者包括Adaccine、ApolloBio公司、阿斯利康公司、比爾和梅林達·蓋茨基金會、防疫創新聯盟(CEPI)、國防高級研究計劃局(DARPA)/化學、生物、輻射和核防禦聯合項目執行辦公室(JPEO-CBRND)/國防部(DoD)、艾滋病毒疫苗試驗網絡、國際疫苗研究所(IVI)、卡內卡Eurogentec、醫學CBRN防禦聯盟(Plebline生命科學，Regeneron，Richter-Helm生物製品，Thermo Fisher Science，賓夕法尼亞大學，沃爾特·裏德陸軍研究所, 和維斯塔爾研究所。Inovio還自豪地獲得了2020年度女性董事會“W”稱號，表彰董事會中女性比例超過20%的公司。欲瞭解更多信息，請訪問www.inovio.com。
CONTACTS:
聯繫人：
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
媒體：傑夫·理查森(Jeff Richardson)電話：267-440-4211電子郵件：jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
投資者：本·馬通(Ben Matone)電話：484-362-0076電子郵件：ben.matone@inovio.com
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
本新聞稿包含一些與我們的業務相關的前瞻性陳述，包括我們開發和商業化DNA藥物的計劃。不能保證我們正在籌備中的任何候選產品將被成功開發、製造或商業化，不能保證臨牀試驗的最終結果將支持上市產品所需的監管批准，也不能保證本文提供的任何前瞻性信息將被證明是準確的。前瞻性陳述僅在本新聞稿發佈之日發表，除非法律要求，否則我們不承擔更新或修改這些陳述的義務。
View original content:http://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-michael-cordera-as-executive-vice-president--general-counsel-301247078.html
查看原始content:http://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-michael-cordera-as-executive-vice-president--general-counsel-301247078.html
SOURCE INOVIO Pharmaceuticals, Inc.
來源：Inovio製藥公司
/Web site: www.inovio.com
網址：www.inovio.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 15, 2021 08:00 ET (12:00 GMT)
2021年3月15日東部時間08：00(格林尼治標準時間12：00)
譯文內容由第三人軟體翻譯。